Sabah Ali Al-Qadasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sabah Ali Al-Qadasi has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Amel Sobhey El- Sedfy
Alexandria University- Medical Research Institute
1 shared publication- Mona Abdel- Hamed Yahia
Alexandria University
1 shared publication - Shawky Mohamed El-Fiky
Alexandria University Medical Research Institute
1 shared publication
Latest Publications
- Open Access
- 5 October 2020
- Published by Springer Nature in Research Square
Quantitative Immunohistochemical Expression of GP88 in Invasive Ductal Carcinoma (IDC) of Human Breast Cancer
Background: Progranulin or acrogranin is an 88-kDa glycoprotein identified by a biological screen for protein targets associated with high tumorigenicity. This work was aimed to investigate the digital expression of GP88, and HER2/neu as a predictive biomarker in human invasive ductal carcinoma (IDC) versus benign tumors and normal breast tissues, as well as, its correlation with different pathological parameters.Methods: The immunohistochemical avidin-biotin complex protocol of the paraffin section was used to detect the expression of GP88 and HER2/neu in IDC of 60 patients, 30 benign, and ten normal breast tissues. Results: the study showed a high expression of GP88 in IDC comparing to normal and benign breast tissues. A higher significant statistical correlation between the expression of GP88 and large tumor size, tumor grade, and lymph node metastasis (LNM). While a negative statistical correlation was noticed between the expression of GP88 and ER, PR, and HER2/neu status.Conclusion: It could be concluded that GP88 glycoprotein may be a valuable predictive and therapeutic marker in human IDC patients.
- 5 October 2020
- Published by Springer Nature in Research Square
Open AccessQuantitative Immunohistochemical Expression of GP88 in Invasive Ductal Carcinoma (IDC) of Human Breast Cancer
Background: Progranulin or acrogranin is an 88-kDa glycoprotein identified by a biological screen for protein targets associated with high tumorigenicity. This work was aimed to investigate the digital expression of GP88, and HER2/neu as a predictive biomarker in human invasive ductal carcinoma (IDC) versus benign tumors and normal breast tissues, as well as, its correlation with different pathological parameters.Methods: The immunohistochemical avidin-biotin complex protocol of the paraffin section was used to detect the expression of GP88 and HER2/neu in IDC of 60 patients, 30 benign, and ten normal breast tissues. Results: the study showed a high expression of GP88 in IDC comparing to normal and benign breast tissues. A higher significant statistical correlation between the expression of GP88 and large tumor size, tumor grade, and lymph node metastasis (LNM). While a negative statistical correlation was noticed between the expression of GP88 and ER, PR, and HER2/neu status.Conclusion: It could be concluded that GP88 glycoprotein may be a valuable predictive and therapeutic marker in human IDC patients.